Adam Feuerstein ✡️ ✓

@adamfeuerstein · Boston, MA · joined 05 Jan 2010

Biotech reporter @statnews. Dog ❤️er. Polk Award winner. #COYS. Said one analyst: The likes of Adam Feuerstein attack viciously. On Signal: stataf.54

131 166Followers

802Following

84 571Posts total

649.4KViews on collected posts

Against accounts of the same size

4 posts from the last 90 days, next to the 100K–1M follower range. shown widely, but few of those viewers react.

Median views21 884this account21 891median for 100K–1M

Reach, %16.68%this account6.81%median for 100K–1M

Engagement, %0.34%this account1.14%median for 100K–1M

Metric	This account	Median for 100K–1M	Ratio
Median views per post	21 884	21 891	1.00×
Reach (views ÷ followers)	16.68%	6.81%	2.45×
Engagement rate	0.34%	1.14%	0.30×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

570.7K24 Oct

22.9K2 Sep

24.7K

10.2K

20.8K

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.04%24 Oct

0.42%2 Sep

0.26%

0.57%

0.17%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 1.14%.

What the audience does

Likes66.7%364 in total

Reposts4.8%26 in total

Replies14.3%78 in total

Quotes3.1%17 in total

Bookmarks11.2%61 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

Ultragenyx $RARE drug to treat Angelman syndrome, a rare disease, fails late-stage trial https://t.co/wPySlAvJhn via @Jasonmmast 20.8K views · 29 likes · 2 reposts · 2 replies 02 Sep 2026 No spin in the $RARE Angelman study press release. Disappointing results for everyone, but no excuses either. 10.2K views · 54 likes · 2 reposts · 2 replies 02 Sep 2026 Ultragenyx $RARE announces Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve primary endpoint 24.7K views · 52 likes · 2 reposts · 7 replies 02 Sep 2026 Follow-up on $QURE confirmatory study in Huntington's, per Sami Corwin at William Blair: "Alignment reached on key elements of confirmatory trial. In a follow-up with management, it indicated that the company reached alignment on the key elements of the confirmatory trial. The 22.9K views · 78 likes · 9 reposts · 4 replies 02 Sep 2026 Friends - My humble request is that you sign up for the email version of my weekly newsletter. Its contents are also posted on STAT's website, but the email arrives every Thursday at 6:30 am ET which means you can hate-read it over coffee. https://t.co/eTSvvKY03i 570.7K views · 151 likes · 11 reposts · 63 replies 24 Oct 2024